The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis by O'Donoghue Michelle, Antman Elliott M, Braunwald Eugene, Murphy Sabina A, Steg P Gabriel, Finkelstein Ariel, Penny William F, Fridrich Viliam, McCabe Carolyn H, Sabatine Marc S, Wiviott Stephen D in Journal of the American College of Cardiology (2009).

[PMID: 19679245] PubMed


Discussed In Paper


Dosing Information

No dosing information annotated.